Abstract:BACKGROUND Colorectal cancer (CRC) ranks among the most prevalent malignant tumors globally. Recent reports suggest that Fusobacterium nucleatum (F. nucleatum ) contributes to the initiation, progression, and prognosis of CRC. Butyrate, a short-chain fatty acid derived from the bacterial fermentation of soluble dietary fiber, is known to inhibit various cancers. This study is designed to explore whether F. nucleatum influences the onset and progression of CRC by impacting the intestinal metabolite butyric acid. AIM To investigate the mechanism by which F. nucleatum affects CRC occurrence and development. METHODS Alterations in the gut microbiota of BALB/c mice were observed following the oral administration of F. nucleatum . Additionally, DLD-1 and HCT116 cell lines were exposed to sodium butyrate (NaB) and F. nucleatum in vitro to examine the effects on proliferative proteins and mitochondrial function. RESULTS Our research indicates that the prevalence of F. nucleatum in fecal samples from CRC patients is significantly greater than in healthy counterparts, while the prevalence of butyrate-producing bacteria is notably lower. In mice colonized with F. nucleatum , the population of butyrate-producing bacteria decreased, resulting in altered levels of butyric acid, a key intestinal metabolite of butyrate. Exposure to NaB can impair mitochondrial morphology and diminish mitochondrial membrane potential in DLD-1 and HCT116 CRC cells. Consequently, this leads to modulated production of adenosine triphosphate and reactive oxygen species, thereby inhibiting cancer cell proliferation. Additionally, NaB triggers the adenosine monophosphate-activated protein kinase (AMPK) signaling pathway, blocks the cell cycle in HCT116 and DLD-1 cells, and curtails the proliferation of CRC cells. The combined presence of F. nucleatum and NaB attenuated the effects of the latter. By employing small interfering RNA to suppress AMPK, it was demonstrated that AMPK is essential for NaB’s inhibition of CRC cell proliferation. CONCLUSION F. nucleatum can promote cancer progression through its inhibitory effect on butyric acid, via the AMPK signaling pathway.

Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer

Fusobacterium Nucleatum Subspecies Animalis Influences Proinflammatory Cytokine Expression and Monocyte Activation in Human Colorectal Tumors.

Fusobacterium nucleatum Acts as a Pro-carcinogenic Bacterium in Colorectal Cancer: From Association to Causality

Fusobacterium nucleatum and colorectal cancer: A review

Fusobacterium nucleatum and colorectal cancer: From phenomenon to mechanism

The role of Fusobacterium nucleatum in colorectal cancer: from carcinogenesis to clinical management

The Role of Fusobacterium nucleatum in Colorectal Cancer Cell Proliferation and Migration

The Role of Fusobacterium nucleatum in Oral and Colorectal Carcinogenesis

Fusobacterium and Colorectal Cancer

Association between Fusobacterium nucleatum and colorectal cancer: Progress and future directions

EXPRESS: The role of Fusobacterium nucleatum in the pathogenesis of colon cancer

Fusobacterium nucleatum in tumors: from tumorigenesis to tumor metastasis and tumor resistance

The Potential Role of Fusobacterium nucleatum

Fusobacterium nucleatum Accelerates the Progression of Colitis-Associated Colorectal Cancer by Promoting EMT

Association of Fusobacterium nucleatum infection with the clinicopathological characteristics in colorectal cancer patients

Fusobacterium nucleatum - symbiont, opportunist and oncobacterium

Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β‐catenin modulator Annexin A1

Dysbiosis Signature of Fecal Microbiota in Colorectal Cancer Patients

Fusobacterium nucleatum promotes colorectal cancer cells adhesion to endothelial cells and facilitates extravasation and metastasis by inducing ALPK1/NF-κB/ICAM1 axis

Fusobacterium nucleatum -induced imbalance in microbiome-derived butyric acid levels promotes the occurrence and development of colorectal cancer

Application of Fusobacterium nucleatum as a biomarker in gastrointestinal malignancies